<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232791</url>
  </required_header>
  <id_info>
    <org_study_id>EC03-04</org_study_id>
    <nct_id>NCT00232791</nct_id>
  </id_info>
  <brief_title>The Study to Compare Cypher Versus Cypher Select in Treating Cornary Artery Lesions.</brief_title>
  <acronym>DOMINO</acronym>
  <official_title>A Randomized Study With the CYPHER SELECT™ Sirolimus-Eluting Balloon-Expandable Coronary Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the CYPHER
      SELECT™ Sirolimus-eluting Coronary Stent in reducing angiographic in-stent late loss in de
      novo native coronary lesions as compared to the CYPHER ™ Sirolimus-eluting Coronary Stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (up to 10 sites), open, prospective, 2-arm, unbalanced, randomized
      study designed to assess the safety and effectiveness of the CYPHER SELECT™ Sirolimus-eluting
      Coronary Stent as compared to the CYPHER™ Sirolimus-eluting Coronary Stent. A total of 100
      patients will be entered in the study and will be randomized on a 2:1 basis to the CYPHER
      SELECT™ stent or the CYPHER™ stent. 100 patients with de novo native coronary artery lesions
      &lt;23 mm in length and more than 2.5 to less than 3.5 mm in diameter by visual estimate who
      meet all eligibility criteria will be either randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic in-stent late loss</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent mean percent diameter stenosis</measure>
    <time_frame>anytime post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-target vessel segment MLD</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent MLD</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent volume of restenosis determined by IVUS</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYPHER SELECT™ Sirolimus-eluting Coronary Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYPHER™ Sirolimus-eluting Coronary Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher Select</intervention_name>
    <description>CYPHER SELECT™ Sirolimus-eluting Coronary Stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PTCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher</intervention_name>
    <description>CYPHER™ Sirolimus-eluting Coronary Stent</description>
    <arm_group_label>2</arm_group_label>
    <other_name>PTCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II-III) OR patients with documented silent ischemia;

          2. Single treatment of de novo lesion in a coronary artery which can be appropriately
             covered by a study stent up to 23mm in length in patients with single or multivessel
             disease; patients with multiple lesions can be included only if the other lesions are
             successfully treated before the target lesion;

          3. Target lesion is more than 2.5 and less than 3.5mm in diameter (visual estimate);

          4. Target lesion is located in a native coronary artery with a maximum lesion length that
             can be adequately covered by a single 23 mm stent;

          5. Target lesion stenosis is &gt; 50% and &lt; 100% (visual estimate).

        Exclusion Criteria:

          1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the
             CK and CK-MB enzymes are back to normal;

          2. Unprotected left main coronary disease with more than 50% stenosis;

          3. Significant (&gt;50%) stenoses proximal or distal to the target lesion that might require
             revascularization or impede runoff;

          4. Have an ostial target lesion;

          5. Angiographic evidence of thrombus within target lesion;

          6. Calcified lesions which cannot be successfully predilated;

          7. Ejection fraction less than 30%;

          8. Totally occluded vessel (TIMI 0 level);

          9. Direct Stenting;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. H. Stables, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiothoracic Centre Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiothoracic Center Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>August 5, 2008</last_update_submitted>
  <last_update_submitted_qc>August 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll, Director Clinical Affairs</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

